Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

China · Delayed Price · Currency is CNY

7.42

-0.02 (-0.27%)

Aug 4, 2026, 3:00 PM CST

Cabio Biotech (Wuhan) Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	418.18	563.14	555.59	443.8	433.42	351.11
Revenue Growth	-29.66%	1.36%	25.19%	2.40%	23.44%	8.55%
Gross Profit	163.31	250.37	223.72	179.29	176.29	178.78
Operating Income	41.17	129.54	97.9	76.08	64.35	101.7
Net Income	55.16	143.72	124.21	91.37	64.37	128.58
Earnings Per Share	0.33	0.86	0.74	0.54	0.38	0.76
EPS Growth	-62.21%	16.22%	37.04%	42.10%	-50.28%	-1.84%

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
ARA	387.61
DHA	123.6
Total	511.21

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	386.85	278.23	153.18	239.71	527.13	675.97
Total Debt	206.71	86.28	19.29	12.76	33.05	2.42
Net Cash (Debt)	180.14	191.95	133.89	226.95	494.08	673.55
Net Cash Growth	16.09%	43.37%	-41.01%	-54.07%	-26.65%	-21.76%
Net Cash Per Share	1.08	1.15	0.80	1.34	2.92	4.00

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	224.45	270.07	173.04	68.89	176.4	103.29
Capital Expenditures	-127.32	-144.54	-211.6	-297.68	-249.47	-173.43
Free Cash Flow	97.13	125.53	-38.55	-228.79	-73.07	-70.14
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	39.05%	44.46%	40.27%	40.40%	40.67%	50.92%
Operating Margin	9.85%	23.00%	17.62%	17.14%	14.85%	28.97%
Pretax Margin	15.65%	28.82%	25.17%	22.53%	18.03%	43.31%
Profit Margin	13.19%	25.52%	22.36%	20.59%	14.85%	36.62%
FCF Margin	23.23%	22.29%	-6.94%	-51.55%	-16.86%	-19.98%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.201	-	0.201	0.200	0.214	0.236
Dividend Per Share Growth	0.47%	-	0.47%	-6.67%	-9.08%	0%
Dividend Yield	2.71%	-	1.06%	1.14%	0.69%	0.56%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	22.51	27.02	25.79	32.97	84.48	57.34
Forward PE	-	19.04	22.89	23.21	32.26	38.73
P/FCF Ratio	12.57	30.93	-	-	-	-
PS Ratio	2.92	6.90	5.77	6.79	12.55	21.00